NCT01055821View on ClinicalTrials.gov

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

August 31, 2013

Conditions
Chronic Hepatitis C Infection
Interventions
DRUG

pegylated interferon and ribavirin

48 weeks

BIOLOGICAL

TG4040 + SOC

6 injections

BIOLOGICAL

TG4040 + SOC

13 injections

Trial Locations (1)

Unknown

Hospital, Hanover

Sponsors

Lead Sponsor

Transgene
All Listed Sponsors
lead

Transgene

INDUSTRY